자임웍스 (ZYME) 주가

자임웍스(ZYME)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $26.60 (-3.20%), 시가총액 $1.83B, 52주 최저~최고 $11.22 ~ $28.56.

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuv

핵심 지표

• 현재가: $26.60 (-3.20%)
• 시가총액: $1.83B
• 52주 최저~최고: $11.22 ~ $28.56
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

자임웍스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

자임웍스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 11.17
• 순이익률: -1.26%
• 영업이익률: -19.57%

자주 묻는 질문